ATE490264T1 - Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen - Google Patents

Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen

Info

Publication number
ATE490264T1
ATE490264T1 AT04761605T AT04761605T ATE490264T1 AT E490264 T1 ATE490264 T1 AT E490264T1 AT 04761605 T AT04761605 T AT 04761605T AT 04761605 T AT04761605 T AT 04761605T AT E490264 T1 ATE490264 T1 AT E490264T1
Authority
AT
Austria
Prior art keywords
spaciously
macrocyclic compounds
drug discovery
compounds suitable
defined macrocyclic
Prior art date
Application number
AT04761605T
Other languages
English (en)
Inventor
Pierre Deslongchamps
Yves Dory
Mark Peterson
Kamel Benakli
Eric Marsault
Luc Ouellet
Mahesh Ramaseshan
Martin Vezina
Daniel Fortin
Ruoxi Lan
Shigui Li
Gerald Villeneuve
Hamid Hoveyda
Sylvie Beaubien
Graeme Fraser
Original Assignee
Tranzyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma Inc filed Critical Tranzyme Pharma Inc
Application granted granted Critical
Publication of ATE490264T1 publication Critical patent/ATE490264T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04761605T 2003-07-31 2004-08-02 Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen ATE490264T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49124803P 2003-07-31 2003-07-31
PCT/CA2004/001439 WO2005012331A1 (en) 2003-07-31 2004-08-02 Spatially-defined macrocyclic compounds useful for drug discovery

Publications (1)

Publication Number Publication Date
ATE490264T1 true ATE490264T1 (de) 2010-12-15

Family

ID=34115484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04761605T ATE490264T1 (de) 2003-07-31 2004-08-02 Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen

Country Status (15)

Country Link
US (3) US7452862B2 (de)
EP (3) EP1648922B9 (de)
JP (1) JP4928262B2 (de)
AT (1) ATE490264T1 (de)
AU (1) AU2004261329B2 (de)
CA (1) CA2533818C (de)
CY (1) CY1111901T1 (de)
DE (1) DE602004030344D1 (de)
DK (1) DK1648922T3 (de)
ES (1) ES2357235T7 (de)
IL (1) IL173312A0 (de)
PL (1) PL1648922T3 (de)
PT (1) PT1648922E (de)
SI (1) SI1648922T1 (de)
WO (1) WO2005012331A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
DK1633774T3 (da) 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
CA2533820C (en) * 2003-07-31 2016-12-13 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
JP5739766B2 (ja) * 2004-06-18 2015-06-24 オセラ セラピューティクス， インコーポレイテッド グレリン受容体の大環状モジュレーターの使用方法
WO2006046977A1 (en) * 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and methods of using the same
CA2583345A1 (en) * 2005-06-13 2006-12-28 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
SI1907374T1 (sl) * 2005-07-26 2012-11-30 Glaxo Group Ltd Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
EP2431380A3 (de) 2006-09-11 2013-07-03 Tranzyme Pharma, Inc. Makrozyklischer Antagonist des Motilinrezeptors zur Behandlung von Magen-Darm-Motilitätsstörungen
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
KR101575703B1 (ko) 2009-02-27 2015-12-10 라퀄리아 파마 인코포레이티드 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체
US9662126B2 (en) 2009-04-17 2017-05-30 Arthrosurface Incorporated Glenoid resurfacing system and method
EP2493910A1 (de) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Makrozyklische ghrelin-rezeptorantagonisten und gegenagonisten sowie verwendungsverfahren dafür
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2011105310A1 (en) * 2010-02-26 2011-09-01 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
US20130316391A1 (en) 2010-12-29 2013-11-28 Sigmaaldrich Co., LLC Cells having disrupted expression of proteins involved in adme and toxicology processes
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
CN103113404B (zh) * 2013-02-22 2015-09-23 广州巨元生化有限公司 一种制备4-二烃氧基膦酰基-2-甲基-2-丁烯酸烃基酯的方法
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CA2998885C (en) 2015-09-24 2020-09-01 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
AU2016347456B2 (en) 2015-10-27 2018-12-13 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CA3024071C (en) * 2016-05-16 2023-02-21 Cyclenium Pharma Inc. Libraries of diverse macrocyclic compounds and methods of making and using the same
US20180110824A1 (en) * 2016-10-21 2018-04-26 Ocera Therapeutics, Inc. Macrocyclic Modulators of the Ghrelin Receptor
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (de) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetische spirochromanverbindungen
EP3388444A1 (de) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Antibakterielle peptidmakrozyklen und verwendung davon
WO2018232062A1 (en) 2017-06-15 2018-12-20 University Of Washington Macrocyclic polypeptides
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US12358948B2 (en) 2019-02-08 2025-07-15 Socpra Sciences Santé Et Humaines S.E.C. Neurotensinergic agonists and methods of using same preventing or treating pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235377A1 (de) * 1971-07-30 1973-02-08 Banyu Pharma Co Ltd 2,4-thiazol-dimethanol-carbamat und verfahren zu dessen herstellung
GB1365201A (en) 1971-07-30 1974-08-29 Banyu Pharma Co Ltd 2 4 thiazoledimethanol carbamates and 2 4-thiazoledimethanol
US3997540A (en) 1975-07-21 1976-12-14 Burroughs Wellcome Co. O [(O-piperazinocarbonyl-phenyl)-thio]-benzoates
US4382090A (en) * 1980-10-02 1983-05-03 Eli Lilly And Company N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds
US5514786A (en) * 1990-01-11 1996-05-07 Isis Pharmaceuticals, Inc. Compositions for inhibiting RNA activity
WO1996022304A1 (en) 1995-01-20 1996-07-25 Molecumetics, Ltd. Conformationally constrained reverse-turn library and methods relating thereto
US5646285A (en) 1995-06-07 1997-07-08 Zymogenetics, Inc. Combinatorial non-peptide libraries
US5891737A (en) 1995-06-07 1999-04-06 Zymogenetics, Inc. Combinatorial non-peptide libraries
IL117426A (en) * 1996-03-10 2005-09-25 Yissum Res Dev Co Synthetic pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same
US5712253A (en) * 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO1998046631A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
US20020068301A1 (en) 1997-05-28 2002-06-06 Hung-Sen Lai Cyclic peptide libraries and methods of use thereof to identify binding motifs
US6165985A (en) * 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
CA2284459C (en) * 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
DE60140285D1 (de) * 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
CN1443198A (zh) 2000-07-24 2003-09-17 阿达纳生物科学有限公司 Ghrelin拮抗剂
US6653334B1 (en) 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
DK1633774T3 (da) * 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
CA2533820C (en) * 2003-07-31 2016-12-13 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция

Also Published As

Publication number Publication date
DK1648922T3 (da) 2011-03-14
EP1648922B1 (de) 2010-12-01
EP2319859A3 (de) 2011-12-21
US7452862B2 (en) 2008-11-18
ES2357235T3 (es) 2011-04-20
WO2005012331A1 (en) 2005-02-10
EP1648922A1 (de) 2006-04-26
US20110237785A1 (en) 2011-09-29
CA2533818A1 (en) 2005-02-10
US8440851B2 (en) 2013-05-14
IL173312A0 (en) 2009-02-11
CY1111901T1 (el) 2015-11-04
CA2533818C (en) 2015-03-17
EP2319859B1 (de) 2013-03-27
AU2004261329A1 (en) 2005-02-10
JP2007527863A (ja) 2007-10-04
US20090137817A1 (en) 2009-05-28
EP2316846A3 (de) 2012-04-04
SI1648922T1 (sl) 2011-03-31
EP1648922B9 (de) 2013-04-03
PL1648922T3 (pl) 2011-05-31
EP1648922B3 (de) 2012-08-15
EP2316846B1 (de) 2019-10-02
JP4928262B2 (ja) 2012-05-09
EP2316846A2 (de) 2011-05-04
US20050137127A1 (en) 2005-06-23
EP2319859A2 (de) 2011-05-11
EP1648922A4 (de) 2006-08-23
ES2357235T7 (es) 2013-02-14
ES2357235T8 (es) 2011-06-06
US8022252B2 (en) 2011-09-20
PT1648922E (pt) 2011-01-04
AU2004261329B2 (en) 2011-10-27
DE602004030344D1 (de) 2011-01-13

Similar Documents

Publication Publication Date Title
ATE490264T1 (de) Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen
DE602004018782D1 (de) Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
UY28693A1 (es) Compuestos utiles en terapia
DE60219469D1 (de) Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika
BRPI0605921A2 (pt) compostos orgánicos
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
NO20062040L (no) Modulatorer for atp-bindende kassett-transportere inneholdende cykloalkyl eller pyranylgrupper
ATE463294T1 (de) Verfahren zur konzentration und reinigung von biologischen verbindungen
PL313392A1 (en) Determination set
NO20060775L (no) Muskarine acetylkolinreseptorantagonister
ATE407929T1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, ihre verwendung und verfahren zu ihrer herstellung
DE502007006901D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE544073T1 (de) Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a- komplexe in einer blutprobe
ATE537259T1 (de) Modifizierte beta-lactamasen und deren verwendung
WO2004113574A3 (en) Methods for disease screening
DE60315308D1 (de) VERFAHREN ZUR HERSTELLUNG VON 5-(4-FLUORPHENYL)-1-i2-((2R,4R)-4-HYDROXY-6-OXOTETRAHYDROPYRAN-2-YL)ETHYLö-2-ISOPROPYL-4-PHENYL-1H-PYRROL-3-CARBONSÄUREPHENYLAMID
DE59814032D1 (de) Nucleinsäuremolekül, kit und verwendung
TW200630614A (en) Bioassey device and method
WO2006080937A3 (en) Screening assays for antimicrobial agents
DK1270576T3 (da) 3-phenyl-3,7-diazabicyclo[3,3,1]nonan-forbindelser samt fremgangsmåde til fremstilling heraf og lægemidler indeholdende sådanne forbindelser
WO2006001986A3 (en) Glut3 transporters expressed in cancer cells
Pierce Young Career Focus: Dr. Joshua Pierce (North Carolina State University, USA)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648922

Country of ref document: EP